Abstract
BackgroundRandomized trials evaluating programmed cell death protein 1 (PD-1) inhibitors in metastatic melanoma either permitted treatment for 2 years (pembrolizumab) or more (nivolumab). The optimal duration of therapy is currently...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have